Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 11/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL1707063 | 0.94 | PIN1 (0.54) | PIN1ABCG2EGFRALDH1A1LMNA | |
| Bicarbonate SCHEMBL1707062 | 0.94 | PIN1 (0.54) | PIN1ABCG2EGFRALDH1A1LMNA | |
| Bicarbonate SCHEMBL1707061 | 0.93 | PIN1 (0.53) | PIN1ABCG2EGFRALDH1A1LMNA | |
| SCHEMBL21358342 | 0.87 | PIN1 (0.57) | PIN1ABCG2EGFRALDH1A1LMNA | |
| SCHEMBL12519771 | 0.87 | PIN1 (0.57) | PIN1ABCG2ALDH1A1LMNAGAA | |
| SCHEMBL16370549 | 0.85 | PIN1 (0.64) | PIN1ABCG2EGFRALDH1A1LMNA | |
| SCHEMBL30672838 | 0.85 | PIN1 (0.64) | PIN1ABCG2EGFRALDH1A1LMNA | |
| SCHEMBL1707043 | 0.83 | PIN1 (0.58) | PIN1EGFRLMNAMAPTKMT2A | |
| SCHEMBL23243727 | 0.81 | ABCG2 (0.54) | PIN1ABCG2EGFRALDH1A1LMNA | |
| SCHEMBL10847463 | 0.80 | LMNA (0.56) | PIN1ABCG2EGFRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777652-A | Method for preparing 2,5-dichloro-4-(3-nitrophenoxy) pyrimidine | 戊言医药科技（上海）有限公司 | 2016-07-20 | — | — | CN | claimed |
| EP-4745127-A1 | PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Technoderma Medicines Inc. (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025011444-A1 | PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 特科罗生物科技(成都)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-3036231-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| CN-106916112-B | Pyrimidine derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | JUBILANT BIOSYS LIMITED (IN) | 2019-04-30 | — | — | US | disclosed |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012151561-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | PIN1 264/4885ABCG2 722/4885EGFR 1/4885 |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | PIN1 788/4885ABCG2 811/4885EGFR 1/4885 |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | EGFR, BRCA1, PTPRJ | PIN1 925/4885ABCG2 3237/4885EGFR 1/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | PIN1 264/4885ABCG2 722/4885EGFR 1/4885 |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | TYMP, EGFR, TK1 | PIN1 863/4885ABCG2 13/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.